Summary
This narrative review in Nature Reviews Clinical Oncology examines antibody–drug conjugates as a class of targeted cancer therapeutics, synthesising evidence on their design principles, tumour-targeting mechanisms, and clinical efficacy across multiple cancer types as of 2021. The authors appear to argue that ADCs represent a promising therapeutic modality with capacity to unlock improved treatment outcomes through precision delivery of cytotoxic payloads. The review likely reflects the emerging clinical validation of several ADC agents in phase II–III trials during this period.
UK applicability
Findings would apply to UK oncology practice through the National Health Service cancer treatment pathways and NICE appraisal processes for novel cancer therapeutics, though the paper is a mechanistic/clinical review rather than a health-system or implementation study.
Key measures
Clinical efficacy endpoints, response rates, safety profiles, and mechanisms of ADC action in cancer therapy
Outcomes reported
The paper reviews the therapeutic potential, clinical efficacy, and mechanistic development of antibody–drug conjugate (ADC) therapies in cancer treatment. It synthesises evidence on ADC design, tumour targeting, and clinical trial outcomes across oncology indications.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.